Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
  • Patent number: 11326150
    Abstract: The present invention provides a means for reconstituting tissues and organs having mature functions. A method of preparing a tissue or an organ, comprising coculturing an organ cell with a vascular endothelial cell and a mesenchymal cell, generating an organ bud, transplanting the organ bud into a non-human animal, and then isolating from the non-human animal the transplanted organ bud-derived tissue or organ.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: May 10, 2022
    Assignee: Public University Corporation Yokohama City University
    Inventors: Hideki Taniguchi, Takanori Takebe
  • Patent number: 11319342
    Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 3, 2022
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Timothy Paul Cleland, Deepak Vashishth
  • Patent number: 11312934
    Abstract: The present invention discloses a piezoelectric ultrasonic microinjection device based on a flexible hinge mechanism. The device includes: a cover, a flexible hinge mechanism, a base, a screw cap and an end cap fixedly assembled together, the base being provided with a pump interface; and a micropipette fixedly mounted in the base, the screw cap and the end cap and extending outward, the micropipette being in communication with the pump interface; wherein the flexible hinge mechanism comprises a housing, a piezoelectric ceramic package module encapsulated in the housing, a central shaft fixedly mounted with the piezoelectric ceramic package module and the base, and a vibration output shaft extending from the piezoelectric ceramic package module into the central shaft, a plurality of flexible hinge beams being disposed between the central shaft and the housing.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 26, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Haibo Huang, Xiwei Gao, Liguo Chen, Fei Zhou, Hao Guo, Lingfeng Chang, Jizhu Liu, Yangjun Wang, Lining Sun
  • Patent number: 11298088
    Abstract: A cone-beam computed tomography (CBCT) method uses a continuous beam and an area detector to carry out fast acquisition of projection data. The acquired projection data are then reconstructed to generate tomographic images. In acquisition of the projection data, a radiation source continuously irradiates a subject with a cone beam of radiation from a plurality of angles and an area detector continuously reads out data. A CBCT system including a source operable to produce a cone beam of radiation and an area detector movable in synchrony with the source to rapidly acquire projection data for CBCT construction is also disclosed.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: April 12, 2022
    Assignee: Varian Medical Systems International AG
    Inventors: Mathias Lehmann, Reto Ansorge, Manuel Waser, Daniel Morf
  • Patent number: 11291688
    Abstract: Methods are disclosed for reducing the proliferation of a tumor cell, increasing apoptosis of a tumor cell, and/or decreasing migration of a tumor cell. These methods include contacting the tumor cell with an effective amount of solubilized ECM or a soluble fraction of extracellular matrix (ECM), thereby reducing the proliferation of the tumor cell, increasing apoptosis of the tumor cell, and/or decreasing migration of the tumor cell. Methods are also disclosed for treating a subject with a tumor. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a soluble fraction of an ECM and a pharmaceutically acceptable carrier, thereby treating the tumor in the subject. In specific non-limiting examples, the tumor is a glioma and/or the ECM hydrogel is a urinary bladder ECM hydrogel.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 5, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Stephen Francis Badylak, George S. Hussey, Lindsey Tamiko Saldin, Mark Hikaru Murdock
  • Patent number: 11286449
    Abstract: The purpose of the present invention is to provide a cell culture substratum which has excellent resistance to liquid culture media and low cytotoxicity, can achieve a high cell adhesion ratio and a high viability of cultured cells, has excellent thermal stability, and is less likely to absorbs ultraviolet ray.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 29, 2022
    Assignees: OHARA, INC., NATIONAL UNIVERSITY CORPORATION NAGAOKA UNIVERSITY OF TECHNOLOGY, NATIONAL INSTITUTE OF TECHNOLOGY
    Inventors: Masahiko Inui, Sunao Chatani, Motohiro Tagaya, Satoshi Motozuka
  • Patent number: 11273445
    Abstract: Provided is a biomimetic chip device. The biomimetic chip device includes a body, a main channel arranged in the body and extending in one direction, a plurality of culture chambers spaced apart from each other on the main channel, a first reservoir arranged at one end of the main channel and storing a first fluid, and a second reservoir arranged at the other end of the main channel and storing the first fluid, wherein the body is tilted about a first axis perpendicular to the one direction to allow the first fluid to flow between the first reservoir and the second reservoir.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 15, 2022
    Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Jin Young Kim, Hong Soo Choi, Eun Hee Kim
  • Patent number: 11261461
    Abstract: Provided are methods and compositions for transdifferentiation of a somatic cell, e.g., a fibroblast to a dopaminergic precursor, Specifically, provided are induced dopaminergic (iDP) cells, or master transcription factors (TFs) therefore, methods for making iDP cells, and methods and compositions for using them in, e.g., treating neurodegenerative diseases such as Parkinson's disease.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: March 1, 2022
    Assignees: Tongji University, Board of Regents of the University of Nebraska
    Inventors: Jialin Zheng, Changhai Tian
  • Patent number: 11261441
    Abstract: The invention provides improved gene therapy vectors, compositions, and methods.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 1, 2022
    Assignees: bluebird bio, Inc., Children's Medical Center Corporation
    Inventors: Gabor Veres, David A. Williams
  • Patent number: 11259510
    Abstract: Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized T cell co-receptor (e.g., humanized CD4 and/or CD8 (e.g., CD8? and/or CD8?)), a human or humanized T cell receptor (TCR) comprising a variable domain encoded by at least one human TCR variable region gene segment and/or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II ? and/or MHC II ? chains) and/or MHC I (e.g., MHC I ?) respectively, and optionally human or humanized ? 2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making a genetically engineered animal that expresses at least one humanized T cell co-receptor (e.g., humanized CD4 and/or CD8), at least one humanized MHC that associates with the humanized T cell co-receptor (e.g., humanized MHC II and/or MHC I, respectively) and/or the humanized TCR are also provided.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 1, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, Christos Kyratsous
  • Patent number: 11261433
    Abstract: An article of manufacture is disclosed which comprises at least two populations of autosomal-identical induced pluripotent stem cells (iPSCs), wherein the complement of sex chromosomes of the first population of the at least two populations is non-identical to the complement of sex chromosomes of the second population of the at least two populations. Uses thereof and methods of generating same are also disclosed.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: March 1, 2022
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Ithai Waldhorn, Benjamin Eithan Reubinoff
  • Patent number: 11261240
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: March 1, 2022
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Diane Hodges, Kei Roger Aoki
  • Patent number: 11254903
    Abstract: The present invention relates to cell culture in bioreactors, such as flexible cellbag bioreactors. More closely the invention relates to a method and system for determining the cell density in a bioreactor culture and for controlling the perfusion rate of a suspension culture of cells in a bioreactor, comprising measuring the oxygen uptake of primary mononuclear cells in a non-static bioreactor.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 22, 2022
    Assignee: CYTIVA SWEDEN AB
    Inventors: Michelle Louise Janas, Aaron Dulgar Tulloch, Clive Glover
  • Patent number: 11254935
    Abstract: Described herein are methods and compositions for producing a gene of interest (GOI) which, in certain embodiments, can reduce the metabolic burden on cells and reduce decoupling of GOI production from marker production, as compared to prior art methods. The methods relate to positive selection and negative selection approaches to establishing high GOI-producing cell lines, e.g., CHO lines. In certain embodiments, the methods comprise transfecting a cell with (a) an oligonucleotide comprising a GOI and a non-coding RNA, and (b) an oligonucleotide encoding a selection protein; wherein the non-coding RNA promotes or inhibits production of the selection protein. The cell producing the GOI can be identified and/or selected as a result of or by detecting the absence or the presence of the selection protein.
    Type: Grant
    Filed: October 3, 2015
    Date of Patent: February 22, 2022
    Assignees: HocusLocus, LLC, Universität fur Bodenkulture
    Inventors: Edward Eveleth, Nicole Borth, Scott A. Tenenbaum, Francis J. Doyle, II, Zachary Edward Wurz
  • Patent number: 11248201
    Abstract: A cell culture vessel including an accommodating part which is an inner space accommodating a cell culture support therein, a fixing member configured to fix the cell culture support to a lower surface of the accommodating part, wherein the fixing member includes a first adhesive layer attached to the lower surface of the accommodating part, a second adhesive layer attached to a lower surface of the cell culture support, and a support film interposed between the first adhesive layer and the second adhesive layer and configured to perform a support function, and an adhesive force between the second adhesive layer and the cell culture support is higher than an adhesive force between the first adhesive layer and the lower surface of the accommodating part.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 15, 2022
    Assignee: AMOLIFESCIENCE CO., LTD.
    Inventors: Seon Ho Jang, Song Hee Koo, In Yong Seo, Seoung Hoon Lee, Chan Kim
  • Patent number: 11236302
    Abstract: The present disclosure relates to methods for producing dopaminergic cells and evaluating their functionality. When pluripotent human embryonic stem cells are cultured on plates coated with laminin-111, laminin-121, laminin-521, laminin-421, or laminin-511 in cell culture medium containing a GSK3 inhibitor and a TGF-? inhibitor as well as timely administered fibroblast growth factor, desired neural cells are produced at far higher rates. Useful cell culture kits for producing such dopaminergic cells are also described herein, as are methods of using such cells for stem cell therapy.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: February 1, 2022
    Assignee: BIOLAMINA AB
    Inventors: Agnete Kirkeby, Malin Pernilla Parmar
  • Patent number: 11235003
    Abstract: The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: February 1, 2022
    Assignee: APOSCIENCE AG
    Inventor: Hendrik Jan Ankersmit
  • Patent number: 11236344
    Abstract: Genetically modified cells with at least one codon substituted to a synonymous codon, and with modified replicative fitness as compared to the unmodified cell, wherein a slower translating synonymous codon increases replicative fitness and a faster translating codon decreased replicative fitness are provided. Further, vaccine composition comprising those cells as well as methods for modifying replicative fitness of a cell are provided.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: February 1, 2022
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Tamir Tuller, Hadas Zur, Rachel Cohen-Kupiec
  • Patent number: 11225682
    Abstract: The present invention is concerned with an automated method for obtaining at least one discrete colony from microorganisms or cells comprised in a solution. This method includes a step where acoustic liquid transfer is employed. The present invention further relates to the use of an acoustic liquid transfer device for obtaining at least one discrete colony from micro organisms or cells comprised in a solution. The present invention also relates to an automated method for determining the presence and/or quantity of microorganisms or cells potentially comprised in a solution and to the use of an acoustic liquid transfer device for determining the presence and/or quantity of microorganisms or cells potentially comprised in a solution.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: January 18, 2022
    Assignee: CureVac AG
    Inventors: Isabel Reichert, Fabian Johannes Eber, Christian Mayer, Aniela Wochner
  • Patent number: 11219869
    Abstract: A membrane structure for moving a gaseous object species from a first region having an object species first concentration, through the membrane structure, to a second region having an object species second concentration different from the first concentration is described. The membrane includes a supporting substrate having a plurality of pores therethrough, each of the plurality of pores defined by a first end, a second end and a surface of the supporting substrate extending between the first end and the second end as well as a nanoporous layer within the plurality of pores, wherein the nanoporous layer comprises a hydrophilic layer and a hydrophobic layer. The membrane also includes a liquid transport medium within the hydrophilic layer. The liquid transport medium includes a liquideous permeation medium and at least one enzyme within the liquideous permeation medium. The at least one enzyme is reinforced by at least one stabilizing component.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 11, 2022
    Inventors: Susan Lynne Rempe, Ying-Bing Jiang, Juan Vanegas, C. Jeffrey Brinker, Joseph L. Cecchi
  • Patent number: 11213385
    Abstract: Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: January 4, 2022
    Assignee: Edwards Lifesciences Corporation
    Inventors: Jeffrey S. Dove, Bin Tian, Ralph Schneider, Jeffrey S. Cohen, Ivan Jankovic, John F. Migliazza, Gregory A. Wright, James M. Young, Louis A. Campbell
  • Patent number: 11213593
    Abstract: Spherical nucleic acids (SNAs), consisting of densely packed, highly oriented polynucleotide strands attached to the surface of nanoparticles, are able to overcome the typical challenges of nucleic acid delivery. The present disclosure demonstrates that G-rich SNAs exhibit several-fold higher uptake into cells relative to SNAs rich in other nucleotides. This disclosure provides an effective strategy to maximize the intracellular delivery of SNAs, which is applicable to other nanoparticle systems, thus establishing an important design consideration for nanoparticle-based intracellular delivery of therapeutics.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: January 4, 2022
    Assignee: Northwestern University
    Inventors: Chad A. Mirkin, Chung Hang J. Choi, Suguna P. Narayan, Liangliang Hao, Evelyn Auyeung
  • Patent number: 11208648
    Abstract: Techniques regarding measuring a position and transcriptome of one or more cells from a biological sample are provided. For example, one or more embodiments described herein can comprise a method, which can comprise covalently bonding a probe to a molecular structure located on a cell to label the cell according to a position of the cell with regards to a biological sample comprising the cell. The probe comprises an oligonucleotide sequence that can be indicative of the position.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 28, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Robert Vogel, Navneet Dogra, Lena Voith von Voithenberg, Aditya Kashyap, Govind V. Kaigala, Gustavo Alejandro Stolovitzky
  • Patent number: 11208623
    Abstract: A disposable polymer container for manipulation of small specimens adapted to optimize heat transfer between an external heating element and specimens herein contained. In particular, this invention relates to the field of containers for Assisted Reproductive Technology hereunder In-vitro fertilization (IVF).
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 28, 2021
    Assignee: HertART ApS
    Inventors: Henrik Carlheim Dörge, Bjarne Bo Jensen
  • Patent number: 11203754
    Abstract: A method comprising administering to a subject a composition comprising an isolated microRNA having a sequence selected from the group consisting of miR-19a-3p (SEQ ID NO:1); miR-103a-3p (SEQ ID NO:2); miR-106b-5p (SEQ ID NO:3); miR-146a-5p (SEQ ID NO:4); miR-223-5p (SEQ ID NO:5); miR-4497 (SEQ ID NO:6); miR-1303 (SEQ ID NO:7); miR-619-5p (SEQ ID NO:8); miR-1273f (SEQ ID NO:9); miR-7851-3p (SEQ ID NO:10); a functional variant thereof; and combinations thereof.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 21, 2021
    Assignee: Advanced ReGen Medical Technologies, LLC
    Inventors: Steven John Greco, Pranela Rameshwar
  • Patent number: 11193128
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: December 7, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Frank Rigo
  • Patent number: 11186810
    Abstract: A cell culture container includes a storage container, a cell culture area, a culture solution supply unit, and a discharge unit. The cell culture area is a region for culturing cells, and is provided in the storage container. The culture solution supply unit supplies the culture solution into the cell culture area at a flow rate equal to or less than a predetermined flow rate. The discharge unit discharges the liquid in the cell culture area to the outside of the storage container. A rectification unit is a structure in which a plurality of outflow ports are uniformly arranged in a direction perpendicular to the flow direction of the culture solution from the culture solution supply unit to the discharge unit.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: November 30, 2021
    Assignees: SHIMADZU CORPORATION, YOKOHAMA CITY UNIVERSITY, OSAKA UNIVERSITY, CORNING INCORPORATED
    Inventors: Tomoki Ohkubo, Masaki Kanai, Hirohisa Abe, Hideki Taniguchi, Masahiro Kinooka, Goro Kobayashi, Takanori Takebe
  • Patent number: 11185100
    Abstract: Amino acids present in domains of an umami taste receptor are described herein, wherein the amino acids interact with at least one nucleotide derivative and/or at least one transmembrane compound that potentiates, modulates, increases, and/or enhances the activity of the umami receptor. Such compounds can be used in flavor compositions to enhance the umami taste and/or palatability of food products.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 30, 2021
    Assignee: MARS, INCORPORATED
    Inventors: Scott Joseph McGrane, Andrew John Taylor, Richard Masten Fine, Boris Klebansky, Matthew Ronald Gibbs
  • Patent number: 11186829
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 30, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Patent number: 11179452
    Abstract: The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: November 23, 2021
    Assignee: VAXIL BIOTHERAPEUTICS LTD.
    Inventor: Lior Carmon
  • Patent number: 11179417
    Abstract: The present invention relates to methods for producing immuno-stimulatory autologous dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from hyper-proliferative disease such as cancer.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: November 23, 2021
    Assignees: Transimmune AG, Yale University
    Inventors: Gunter Bauer, Justin Duckworth, Robert Tigelaar, Richard Edelson, Michael Girardi, Karsten Henco, Adrian Hayday
  • Patent number: 11168301
    Abstract: A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: November 9, 2021
    Assignee: EYESTEM RESEARCH PRIVATE LIMITED
    Inventors: Rajarshi Pal, Rajani Battu, Reena Rathod, Harshini Surendran, Kapil Bharti, Deepak Lamba, Dhruv Sareen, Mahendra Rao, Sushma Nanjunda Swamy, Vijay Bhaskar Konala Reddy, Mohanapriya Rajamoorthy
  • Patent number: 11160879
    Abstract: Provided are a transgenic non-human mammal expressing a fusion protein, wherein the fusion protein comprises an ? subunit of an ATP synthase and two distinct fluorescent proteins as a donor and an acceptor for FRET, one of the fluorescent proteins being placed at an amino terminal moiety of the ? subunit and the other being placed at a carboxyl terminal moiety of the ? subunit, and a method of screening for an agent for preventing or treating diseases in a mammal in need thereof, comprising using an above transgenic non-human mammal.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: November 2, 2021
    Inventor: Masamichi Yamamoto
  • Patent number: 11155870
    Abstract: Method for determining developmental fate of early embryos comprises measuring the expression level of a gene selected from the group consisting of CDKN1C, IGF2R, MAGEL2, MKRN3, NAP1L5, NDN, PEG3, PHLDA2, TSSC4, and UBE3A genes. Also disclosed is a method for improving pregnancy rate, wherein early embryos whose expression level of the MKRN3, NDN, PEG3, PHLDA2, TSSC4, or UBE3A gene is not increased, or the expression level of the CDKN1C, IGF2R, MAGEL2, or NAP1L5 gene is not decreased, are selected for planting into a suitable uterus for further development. Also disclosed are methods for increasing the likelihood of an early embryo to develop successfully into full-term pregnancy, wherein a suitable amount of siRNA corresponding to the PHLDA2 gene is injected into a fertilized egg which is in turn cultured further and planted into a suitable uterus.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Hasan Khatib
  • Patent number: 11141435
    Abstract: Disclosed herein are methods for contacting in a closed container a host liquid including target cells, microbubble reagents comprising gas-core lipid-shelled microbubbles, and one or more antibodies or other ligands that bind to cell surface molecules on the target cells, wherein the one or more antibodies or other ligands are bound to the target cells or the microbubbles, wherein the contacting under conditions to produce target cells linked to microbubbles via the one or more antibodies or other ligands and activating the target cells to generate activated target cells.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: October 12, 2021
    Assignee: ThermoGenesis Corporation
    Inventors: Philip H. Coelho, William Busa, Jonathan Ellis, Dalip Sethi
  • Patent number: 11135528
    Abstract: An extracellular vesicle isolation method using a metal, and a method for isolating extracellular vesicles from various samples using metal affinity are disclosed. An extracellular vesicle isolation method has the advantages of not requiring costly equipment, of being able to be applied without limits on sample quantity, and of being capable of efficiently isolating extracellular vesicles while preserving the shape or properties thereof. Moreover, the method can be combined with existing isolation methods to maximize the efficiency of extracellular vesicle isolation, and can be utilized in disease diagnosis, disease treatment, multi-omics research, and extracellular vesicle property research and the like using the isolated extracellular vesicles.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: October 5, 2021
    Assignee: Rosetta Exosome
    Inventors: Yong Song Gho, Chang Jin Lee, Hyun Taek Park
  • Patent number: 11130943
    Abstract: The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: September 28, 2021
    Assignee: Koninklijke Nederlandse Akademie Van Wetenschappen
    Inventors: Lars Norman Sachs, Jarno Drost
  • Patent number: 11124763
    Abstract: Systems and methods for culturing cells are disclosed. A system can comprise an auxetic scaffold substrate. The substrate can comprise scaffold units at least a portion of which comprise living cells. Scaffold units can be configured to transition between a contracted state and an expanded state. Units can comprise an interior void having a contracted volume in the contracted state and an expanded volume in the expanded state, in which the expanded volume is greater than the contracted volume. Units can be configured to pass a fluid into the interior void of the corresponding unit when the unit transitions from the contracted state to the expanded state. Units can be configured to pass the fluid out of the interior void of the corresponding unit when the unit transitions from the expanded state to the contracted state.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 21, 2021
    Assignee: Georgia Tech Research Corporation
    Inventors: Kan Wang, Ben Wang, Chun Zhang
  • Patent number: 11118196
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 14, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Rebeca Ramos-Zayas
  • Patent number: 11111475
    Abstract: Disclosed herein are neural extracellular vesicles (EVs) and methods of using these EVs in the treatment of spinal cord injury, stroke, and traumatic brain injury and neurodegenerative diseases.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 7, 2021
    Assignees: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., ARUNA BIO, INC.
    Inventors: Steven L. Stice, Robin Lynn Webb, Tracy A. Stice
  • Patent number: 11083744
    Abstract: Therapeutic agents effective for treating cell-proliferative diseases contain extracellular vesicles (exosomes) released from cytotoxic T cells or miRNA obtained from extracellular vesicles (exosomes) released from cytotoxic T cells, such as human CD8+ T cells. Such therapeutic agents suppress the proliferation of mesenchymal cells surrounding cancer cells, e.g., by killing the mesenchymal cells, such that the cancer cells become isolated and unable to metastasize. Cell-proliferative diseases are thus treatable by administering such a therapeutic agent to a patient.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 10, 2021
    Assignees: MIE UNIVERSITY, KYOTO UNIVERSITY
    Inventors: Hiroshi Shiku, Naohiro Seo, Kazunari Akiyoshi, Naozumi Harada, Fumiyasu Momose
  • Patent number: 11085916
    Abstract: A method for observing the dynamics of sweat glands and a method for evaluating a substance of interest, which are useful for development of a preparation for external application, such as a cosmetic. In each of the methods, an observation sample is used, which is prepared by staining all sweat glands, which are isolated alive, with a staining reagent, and then holding the all sweat glands on a support using at least one material selected from the group consisting of collagen, agarose, basement membrane matrix, poly-D-lysine and a membrane.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 10, 2021
    Assignees: MANDOM CORPORATION, OSAKA UNIVERSITY
    Inventors: Kie Nakashima, Ryuichiro Kurata, Fumitaka Fujita, Kiyotoshi Sekiguchi, Atsushi Tanemura, Hiroyuki Murota, Ichiro Katayama
  • Patent number: 11083190
    Abstract: This invention provides gels and matrices having a rigidity in the range of 150-750 Pa, methods of manufacturing same, and method of preserving a mesenchymal stem cell population or studying mesenchymal stem cells, comprising same.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: August 10, 2021
    Inventors: Makoto Funaki, Paul A. Janmey, Jessamine Winer
  • Patent number: 11077169
    Abstract: Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 3, 2021
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter I. Lelkes, Yah-El H. Har-el, Cezary Marcinkiewicz, Philip Lazarovici, Sogol Moaiyed Baharlou, Jonathan A. Gerstenhaber
  • Patent number: 11078495
    Abstract: The present invention provides an integration-defective lentiviral vector based on a parental lentivirus and related methods, the integration-defective lentiviral vector including one or more of the following: (a) a mutation, deletion or other modification of one or more binding sites for a host factor involved in gene silencing; (b) an addition of one or more binding sites for a transcription activator, which can be natural (such as but not limited to ubiquitous and/or tissue/cell type specific) including but not limited to SP1 NFkB, or synthetic including but not limited to binding sites for tetracycline regulated trans activators tTA, rtTA, tT65, and/or rtT65; (c) one or more nucleic acid sequences from a SV40 genome, wherein the one or more sequences are obtained from a region of the SV40 genome upstream to the SV40 poly-adenylation signal; (d) a shRNA expression cassette, which encodes a shRNA directed to a host gene involved in epigenetic silencing and/or in DNA repair pathways; or (e) any combination o
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 3, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Tal Kafri
  • Patent number: 11076868
    Abstract: A vacuum drill guide includes an elongated structure having an internal axial passageway formed therethrough, a first end of the elongated structure terminating in a drill bushing affixed to a first end of the elongated structure, the drill bushing having an axial slot communicating with the internal axial passageway of the elongated structure, the drill bushing further having a longitudinal bore formed therethrough to receive a drill bit and allow the received drill bit to rotate, a second end of the elongated structure opposite the first end terminating in a vacuum hose fitting communicating with the axial passageway, a chip recovery chamber disposed along the internal axial passageway between the first end and the second end of the elongated structure, and a vacuum filter disposed in the internal axial passageway between the chip recovery chamber and the first end of the elongated structure.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: August 3, 2021
    Inventors: Thomas Ward Omohundro, Charles Peter Darby
  • Patent number: 11072649
    Abstract: Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: July 27, 2021
    Assignee: SAB, LLC
    Inventors: Jay Hooper, Eddie Sullivan, Hua Wu
  • Patent number: 11060107
    Abstract: This invention provides purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside, and methods of assessing purity of purified preparations of an RNA, oligoribonucleotide, or polyribonucleotide comprising a modified nucleoside.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: July 13, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Drew Weissman, Katalin Kariko
  • Patent number: 11060062
    Abstract: The present invention relates to a method for generating glucose-responsive beta cells.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: July 13, 2021
    Assignee: University of Copenhagen
    Inventors: Jacqueline Ameri, Henrik Semb
  • Patent number: 11041146
    Abstract: To convert directly from a somatic cell into a cell having the ability to form stratified epithelial tissue that can act as outer skin of the body, a method for producing a cell having the ability to form stratified epithelial tissue is provided, the method including the step of introducing into a somatic cell at least one gene expressed relatively strongly in a cell having the ability to form stratified epithelial tissue.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 22, 2021
    Inventor: Masakazu Kurita